MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

NCT00089076 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
18
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)